Would other oral hypoglycaemics persist as an adequate 1ST line add-on therapy to metformin in patients with type 2 diabetes mellitus? No, it’s time to refocus!

Authors

  • Neerjesh P Lecturer, Motilal Nehru Medical College, Allahabad
  • Rajkishor Singh Assistant Professor, B.R.D Medical College, Gorakhpur
  • Vipender Singh Chopra Professor, Santosh Medical College, Ghaziabad
  • Dharti N Ex- Resident Pacific Dental College& Hospital, Udaipur
  • Kavita Dhar Assistant Professor, Santosh Medical College, Ghaziabad
  • Sanjay Kumar Singh Lecturer, Motilal Nehru Medical College, Allahabad

Keywords:

Sitagliptin, Type 2 diabetes mellitus, Incretin hormone, GLP -1, GIP, Add on to metformin

Abstract

Adequate glycemic control in type 2 diabetes remains a difficult but achievable goal. The development of new classes of glucose-lowering medications, including in particular the incretin-based therapies, provides an opportunity to utilize combinations of medications which target multiple physiologic abnormalities in type 2 diabetes. Complementary combination therapy with sitagliptin–metformin lowers glucose via enhancement of insulin secretion, suppression of glucagon secretion, and insulin sensitization. Use of this combination in diabetes management will provide a greater degree of glycosylated hemoglobin-lowering than that seen with the use of either drug as monotherapy, is unlikely to cause significant hypoglycemia, and is generally associated with weight loss. The effectiveness, tolerability, and potential cost savings associated with the use of sitagliptin–metformin combination therapy make this an attractive option in diabetes management. The possible beneficial effects of this therapy on beta cell function, as well as its cardiovascular impact, remain inadequately explored but are of significant interest.

Downloads

Published

2015-12-16

How to Cite

Neerjesh P, Rajkishor Singh, Vipender Singh Chopra, Dharti N, Kavita Dhar, & Sanjay Kumar Singh. (2015). Would other oral hypoglycaemics persist as an adequate 1ST line add-on therapy to metformin in patients with type 2 diabetes mellitus? No, it’s time to refocus!. World Journal of Pharmaceutical Sciences, 3(12), 2444–2451. Retrieved from https://wjpsonline.com/index.php/wjps/article/view/oral-hypoglycaemics-metformin-diabetes-mellitus

Issue

Section

Review Article

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)